Seeking Alpha·Jun 25, 2026
Valneva SE (VALN) Shareholder/Analyst Call Prepared Remarks TranscriptValneva SE (VALN) Shareholder/Analyst Call Prepared Remarks Transcript
Valneva SE(VALN)Earnings, Financials & Key Ratios
VALN•NASDAQ
$5.40
Price updated Jul 6, 2026
AboutValneva SE, a specialty vaccine company, focuses on the development and commercialization of prophylactic vaccines for infectious diseases with unmet needs. Its commercial vaccines for travelers include IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing Enterotoxigenic Escherichia coli bacterium; and VLA2001, a vaccine candidate against SARS-CoV-2. The company also develops VLA15, a vaccine candidate that has completed Phase II clinical trial against Borrelia; and VLA1553, a vaccine candidate, which is in Phase III clinical trial against the chikungunya virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, other European countries, and internationally. Valneva SE has collaborations with Pfizer, Inc. to co-develop and commercialize its Lyme disease vaccine; and Instituto Butantan for the development, manufacturing, and marketing of single-shot chikungunya vaccine. The company was founded in 1998 and is headquartered in Saint-Herblain, France.Show more
- Revenue$175M+3.0%
- EBITDA-$60M-281.9%
- Net Income-$115M-840.6%
- EPS (Diluted)-1.32-676.5%
- Gross Margin38.66%-7.7%
- EBITDA Margin-34.28%-276.6%
- Operating Margin-46.74%-694.6%
- Net Margin-65.95%-813.2%
- ROE-80.16%-912.8%
VALN Price & Volume
Valneva SE (VALN) stock price & volume — 10-year historical chart
Loading chart...
Persistent Operational Losses Challenge Vaccine Commercialization Strategy
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Liquidity and commercial execution
Key Thesis Takeaways
- Valneva faces significant headwinds as its high-cost, specialized vaccine manufacturing infrastructure struggles to achieve scale, evidenced by a 37.2% year-over-year revenue decline in 2026Q1.
- The company's reliance on lumpy milestone payments and seasonal demand creates substantial volatility, while persistent net losses have eroded the equity base to $76.8M.
- Investors should monitor the firm's ability to manage its $209.7M debt load against a narrowing cash runway of $105.4M, as the current business model remains fundamentally unproven in achieving sustainable operating leverage.
Verdict Logic
the company's operating margin of -76.7% in 2026Q1 and the accumulation of a $711.9M deficit in retained earnings suggest significant execution risks that outweigh current growth prospects.
VALN Growth Metrics
Valneva SE (VALN) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years8.35%
5 Years9.62%
3 Years-21.52%
TTM-15.98%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-71.71%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-41.74%
Return on Capital
10 Years-13.37%
5 Years-18.17%
3 Years-15.06%
Last Year-23.63%
VALN Recent Earnings
Valneva SE (VALN) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 6/12 qtrs (50%)●Beat Revenue 5/12 qtrs (42%)
Q2 2026Latest
May 13, 2026Metric
Actual
Est
EPS
$0.42-100.0%
$0.21
Rev
$36M-33.8%
$55M
Q2 2026
Mar 16, 2026Metric
Actual
Est
EPS
$0.68-293.1%
$0.17
Rev
$56M+6.5%
$52M
Q4 2025
Nov 20, 2025Metric
Actual
Est
EPS
$0.61-103.3%
$0.30
Rev
$34M-29.5%
$49M
Q3 2025
Aug 12, 2025Metric
Actual
Est
EPS
$0.16+40.7%
$0.27
Rev
$57M+45.5%
$39M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 13, 2026 | $0.42vs $0.21-100.0% | $36Mvs $55M-33.8% |
| Q2 2026 | Mar 16, 2026 | $0.68vs $0.17-293.1% | $56Mvs $52M+6.5% |
| Q4 2025 | Nov 20, 2025 | $0.61vs $0.30-103.3% | $34Mvs $49M-29.5% |
| Q3 2025 | Aug 12, 2025 | $0.16vs $0.27+40.7% | $57Mvs $39M+45.5% |
Based on last 12 quarters of dataView full earnings history →
Latest VALN News
Recent stock market news and headlines for Valneva SE (VALN)
GlobeNewsWire·Jun 25, 2026
Valneva Announces Successful Outcome of its Annual General MeetingDr. Gerd Zettlmeissl is appointed as Chair of the Board of Directors Lyon (France), June 25, 2026 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that shareholders approved all resolutions recommended by the Board of Directors at the Company's Annual General Meeting (AGM), held earlier today in Lyon, France. Key resolutions adopted included the approval of the 2025 financial statements, renewal of authorizations granted to the Board of Directors regarding the Company's share capital, and the transfer of Valneva's registered office to Lyon following the closure of its Nantes site.
Peers Comparison
Key metrics vs top competitors for Valneva SE (VALN)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $5.40 | $464.64M | -3.58 | 3% | -65.95% | -80.16% | — | |
| $9.35 | $1.54B | 3.68 | 64.69% | -14.73% | — | — | |
| $0.97 | $35.26M | -4.21 | -64.74% | -245.12% | -1004.96% | — | |
| $8.91 | $9.33B | -23.45 | 668.31% | -606.15% | — | — | |
| $3.75 | $268.97M | 11.36 | -31.8% | 21.61% | 10.62% | — | |
| $23.72 | $134.93B | 17.44 | -1.65% | 11.83% | 8.34% | — |
Compare VALN vs Peers
Valneva SE (VALN) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when VALN posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
VALN Frequently Asked Questions
Valneva SE (VALN) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Valneva SE's revenue?
Valneva SE (VALN) reported $156.3M in revenue for fiscal year 2025. This represents a 5092% increase from $3.0M in 2005.
How fast is Valneva SE growing?
Valneva SE (VALN) grew revenue by 3.0% over the past year. Growth has been modest.
Is VALN profitable?
Valneva SE (VALN) reported a net loss of $138.0M for fiscal year 2025.
Dividend & Returns
What is VALN's return on equity?
Valneva SE (VALN) has a return on equity (ROE) of -80.2%. Negative ROE indicates the company is unprofitable.
What is Valneva SE's free cash flow?
Valneva SE (VALN) had negative free cash flow of $70.9M in fiscal year 2025, likely due to heavy capital investments.